CN114668849B — Shh通路调控生物节律及其相关应用
Assigned to Academy of Military Medical Sciences AMMS of PLA · Expires 2024-01-23 · 2y expired
What this patent protects
本发明涉及生物技术领域,具体涉及Shh通路调控生物节律及其相关应用。具体地,本发明提供了Hedgehog通路抑制剂、SMO抑制剂在调节生物节律、治疗生物节律相关疾病中的应用;优选地,所述Hedgehog通路抑制剂包括PF‑5274857、Mebendazole、HPI‑4、SANT‑1、Taladegib、Glasdegib、Cyclopamine、Itraconazole、GANT61、JK184、Robotnikinin、Vismodegib、Purmorphamine、Sonidegib Phoshate。
USPTO Abstract
本发明涉及生物技术领域,具体涉及Shh通路调控生物节律及其相关应用。具体地,本发明提供了Hedgehog通路抑制剂、SMO抑制剂在调节生物节律、治疗生物节律相关疾病中的应用;优选地,所述Hedgehog通路抑制剂包括PF‑5274857、Mebendazole、HPI‑4、SANT‑1、Taladegib、Glasdegib、Cyclopamine、Itraconazole、GANT61、JK184、Robotnikinin、Vismodegib、Purmorphamine、Sonidegib Phoshate。
Drugs covered by this patent
- Daurismo (Glasdegib Maleate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.